一半海水，一半火焰。 2025年行至尾声，如行业所料，在"并购六条"等政策暖风之下，2025年的A股并购市场迎来了 久违繁荣。 Wind数据显示，今年以来，截至12月23日，A股市场更新的并购重组事件达到6074单（含涉 及多家上市公司的同一重组事件重复统计，下同）。其中， 重大重组数量达到279单，比去年 全年增长接近两倍，已披露的交易总金额高达1.87万亿元，较去年全年增长超过十倍 。 然而，繁荣之下，暗流汹涌。今年更新的重大交易中， 有四分之一以失败收场 ，其中不乏大 市值科技公司发起的产业并购、同一控制权下的交易等。 "乘兴而来，败兴而归"，不仅是大多数并购从业者的内心写照，亦是部分二级市场投资者挥之 不去的阴影。 年中终止的华大九天定增收购芯和半导体、年末终止的海光信息吸收合并中科曙光……从筹划 到终止引发的股价波动，在资本市场引发了不小的争议。年初终止的海尔生物吸收合并上海莱 士，虽然因筹划时间短没有引起股价波动，但复牌后海尔生物股价也出现大跌。 "重大资产重组由于涉及众多环节，本来失败的概率就比较高。而今年市场氛围比较火热，很 多企业不管是从提升质量的角度，还是从二级市场的角度，都有一种很紧迫地 ...

一半海水，一半火焰。 2025年行至尾声，如行业所料，在"并购六条"等政策暖风之下，2025年的A股并购市场迎来了久违繁 荣。 Wind数据显示，今年以来，截至12月23日，A股市场更新的并购重组事件达到6074单（含涉及多家上市 公司的同一重组事件重复统计，下同）。其中，重大重组数量达到279单，比去年全年增长接近两倍， 已披露的交易总金额高达1.87万亿元，较去年全年增长超过十倍。 然而，繁荣之下，暗流汹涌。今年更新的重大交易中，有四分之一以失败收场，其中不乏大市值科技公 司发起的产业并购、同一控制权下的交易等。 "乘兴而来，败兴而归"，不仅是大多数并购从业者的内心写照，亦是部分二级市场投资者挥之不去的阴 影。 年中终止的华大九天定增收购芯和半导体、年末终止的海光信息吸收合并中科曙光……从筹划到终止引 发的股价波动，在资本市场引发了不小的争议。年初终止的海尔生物吸收合并上海莱士，虽然因筹划时 间短没有引起股价波动，但复牌后海尔生物股价也出现大跌。 "重大资产重组由于涉及众多环节，本来失败的概率就比较高。而今年市场氛围比较火热，很多企业不 管是从提升质量的角度，还是从二级市场的角度，都有一种很紧迫地想开始并 ...

Group 1 - The electronic industry saw a net inflow of 4.916 billion yuan, leading the market [1] - The A-share market indices collectively rose, with the Shanghai Composite Index achieving six consecutive days of gains [1] - Among the 13 industries with net inflows, the power equipment and defense industries also saw significant inflows of 2.217 billion yuan and 1.233 billion yuan, respectively [1] Group 2 - A total of 45 stocks experienced net inflows exceeding 200 million yuan, with 15 stocks seeing inflows over 400 million yuan [2] - Demingli topped the list with a net inflow of 955 million yuan, driven by increasing data storage demand influenced by AI [2] - Tianji Co. reached a trading limit with a net inflow of 885 million yuan, focusing on the industrialization of lithium sulfide material preparation [2] Group 3 - At the market close, there was a net inflow of 129 million yuan, with the communication sector leading with over 500 million yuan in inflows [3] - Individual stocks such as Zhongji Xuchuang and Qingshan Paper experienced net inflows exceeding 200 million yuan [3] Group 4 - Beijing Junzheng and Wolong Electric Drive saw net outflows exceeding 100 million yuan at the market close [4] - Companies like Midea Group and Sihua Intelligent Control had net outflows exceeding 70 million yuan [5]

Market Overview - The Shanghai Composite Index rose by 0.53% on December 24, with 26 out of the 28 sectors experiencing gains, led by the defense and electronics sectors, which increased by 2.88% and 2.12% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.24% [1] - The agriculture, forestry, animal husbandry, and fishery sectors, along with coal, were the worst performers, declining by 0.85% and 0.70% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets reached 10.37 billion yuan, with 17 sectors experiencing net inflows [1] - The electronics sector had the highest net inflow, totaling 8.68 billion yuan, coinciding with its 2.12% increase [1] - The power equipment sector also performed well, with a 1.03% increase and a net inflow of 3.76 billion yuan [1] - Conversely, 14 sectors experienced net outflows, with the non-ferrous metals sector leading with a net outflow of 1.635 billion yuan, followed by the basic chemicals sector with 1.212 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector increased by 0.24%, but faced a net outflow of 1.141 billion yuan [2] - Out of 479 stocks in this sector, 320 rose while 134 fell, with one stock hitting the daily limit down [2] - The top three stocks with significant net inflows included C Jianxin with 690 million yuan, followed by Hanyu Pharmaceutical and Innovation Medical with 134 million yuan and 68.69 million yuan respectively [2] - The sector's outflow leaders included Hainan Haiyao with a net outflow of 280 million yuan, followed by Heng Rui Pharmaceutical and Luyan Pharmaceutical with 180 million yuan and 136.53 million yuan respectively [4]

以最新收盘价计算，科创板平均股价为42.60元，其中股价超100元的有81只，股价最高的是寒武纪-U。 证券时报·数据宝统计显示，科创板股今日上涨的有507只，下跌的有90只，以收盘价为基准测算，科创 板平均股价为42.60元，其中，收盘价超过100元的有81只，股价在50元至100元之间的有135只，股价在 30元至50元的有143只。 科创板股中，收盘价最高的是寒武纪-U，今日报收1326.20元，下跌0.74%，其次是源杰科技、摩尔线 程-U等，最新收盘价分别为645.55元、634.01元。 融资融券方面，百元股最新（12月23日）融资余额合计1054.95亿元，融资余额居前的有寒武纪-U、中 芯国际、海光信息等，最新融资余额分别为155.37亿元、130.23亿元、73.90亿元。最新融券余额合计为 4.61亿元，融券余额居前的有海光信息、寒武纪-U、中芯国际等，最新融券余额分别为0.35亿元、0.31 亿元、0.26亿元。（数据宝） 科创板百元股一览 | 代码 | 简称 | 最新收盘价（元） | 今日涨跌（%） | 换手率（%） | 行业 | | --- | --- | --- | --- | - ...

最近股市里不少人盯着融资数据看——毕竟真金白银往里砸的方向，总该有机会吧？可身边朋友却念叨："明明电子、电力设备这些行业融资买得凶，我手 里的股怎么就是不涨？"其实这个问题，早藏在"指数涨了钱没赚"的老麻烦里了。12月23日（周二）Wind统计显示，申万31个一级行业里18个获融资净买 入，电子行业净买入27.65亿元排第一，寒武纪-U、英维克这些个股净买入超2亿。可看着这些数字，有人高兴有人懵：融资砸进去的钱，怎么没落到自己账 户里？别急，文章最后我会说清这个新闻背后的关键，。 很多人觉得牛市是"躺赢局"，可股市本来就有博弈属性——你赚的钱是别人亏的，哪有只赚不赔的道理？反而牛市里交投更活跃，大资金更容易用"假突 破""假回调"骗你下车。就像我邻居买的医药生物股，跟着行业融资净买入进去，结果买在"假企稳"的高点，熬了两周才解套——不是他选的行业不对，是 他没看懂走势背后的"冷处理"。 二、走势里的假动作，比你想的多 一、指数涨了钱没赚，真不是分化的锅 自从10月28日上证指数越过4000点，"赚了指数不赚钱"的吐槽就没断过。有人把这归为市场分化，可我翻了组数据——4月7日上证指数止跌企稳到10月30日 破4 ...

Group 1 - The article discusses various ETFs tracking the Sci-Tech Innovation Board indices, highlighting their focus on high-growth sectors such as semiconductors, medical devices, and software development [2][3] - The Sci-Tech 50 ETF tracks the top 50 stocks by market capitalization and liquidity on the Sci-Tech Innovation Board, with over 65% of its composition in semiconductors and nearly 80% in related sectors [2] - The rolling price-to-earnings (P/E) ratio for the Sci-Tech 50 ETF is reported at 160.0 times, indicating a high valuation level since its inception [2] Group 2 - The Sci-Tech 100 ETF focuses on 100 medium-sized stocks with good liquidity, primarily in the electronics, biomedicine, and electrical equipment sectors, which together account for over 80% of the index [2] - The rolling P/E ratio for the Sci-Tech 100 ETF is noted at 187.8 times, reflecting its valuation dynamics [2] - The Sci-Tech Comprehensive Index ETF covers all market securities on the Sci-Tech Innovation Board, focusing on core industries like artificial intelligence and new energy, with a rolling P/E ratio of 206.9 times [2] Group 3 - The Sci-Tech Growth 50 ETF tracks 50 stocks with high growth rates in revenue and net profit, with nearly 75% of its composition in the electronics and biomedicine sectors [3] - The rolling P/E ratio for the Sci-Tech Growth 50 ETF is reported at 192.0 times, indicating its growth-oriented investment strategy [3] - The article mentions that the management fee for these low-fee products is 0.15% per year, and the custody fee is 0.05% per year [3]

Core Viewpoint - The ChiNext Index is expected to lead the A-share market in 2026, driven by strong performance and the dual themes of technological independence and anti-involution, indicating a new phase of valuation reshaping and value reassessment [1][4]. Group 1: Technological Independence - The ChiNext serves as the main battleground for new productive forces, benefiting from policy dividends and industry trends, particularly in the fields of electric equipment, electronics, and biomedicine [4]. - As of December 19, 2025, over 70% of the market capitalization in ChiNext is concentrated in the core sectors of new information technology, new energy vehicles, and biomedicine [4]. - Profit margins in electric equipment and electronics have stabilized, with some tech sub-sectors experiencing profit growth rates exceeding 40%, reinforcing the investment value of the technology theme [4]. Group 2: Anti-Involution - The anti-involution policy aims to correct vicious competition in industries facing overcapacity and price wars, which could catalyze profit improvements in key ChiNext sectors like new energy and manufacturing [7]. - The policy is expected to optimize industry competition by regulating market order and eliminating outdated capacity, potentially improving supply-demand dynamics and stabilizing product prices and gross margins [7]. - Companies are likely to focus more on genuine technological innovation and efficiency improvements rather than mere scale expansion, enhancing free cash flow and shareholder returns [7]. Group 3: Investment Opportunities in ChiNext - The ChiNext Index's valuation has fallen to a low level, with a TTM price-to-earnings ratio of 39 times as of December 17, 2025, which is in the 37th percentile over the past decade [8]. - The expected net profit growth rates for the ChiNext Index are 38%, 30%, and 23% for the years 2025, 2026, and 2027, respectively, indicating strong profit growth certainty [8]. - Investors are encouraged to consider ChiNext index ETF products, such as E Fund ChiNext ETF, which ranks high in scale and liquidity among similar index products [9].

25家公司公布了全年业绩预告，业绩预增公司有19家，占比76.00%。 | 代码 | 简称 | 业绩预告日 | 预计净利润增幅中值 | 最新收盘价 | 今年以来涨跌幅 | 行业 | | --- | --- | --- | --- | --- | --- | --- | | | | 期 | （%） | （元） | （%） | | | 688796 | 百奥赛 图 | 2025.12.09 | 303.57 | 50.86 | -22.71 | 医药生 物 | | 688802 | 沐曦股 份 | 2025.12.16 | 54.22 | 667.60 | -19.56 | 电子 | （文章来源：证券时报网） 证券时报·数据宝统计显示，截至12月24日，已经有25家公司公布了2025年度业绩预告。业绩预告类型 显示，预增公司19家，报喜公司比例为76.00%；业绩预降、预亏公司分别有2家、1家。 业绩预喜公司中，以预计净利润增幅中值统计，共有1家公司净利润增幅超100%；净利润增幅在 50%~100%之间的有1家。具体到个股看，百奥赛图预计净利润增幅最高。公司预计全年实现净利润增 幅中值为303.57%；沐曦股份 ...

Core Insights - The latest financing balance of the ChiNext market is 546.55 billion yuan, with a week-on-week increase of 3.797 billion yuan, indicating a positive trend in financing activities [1] - On December 23, the ChiNext index rose by 0.41%, and the total margin balance for ChiNext stocks reached 548.40 billion yuan, marking an increase for five consecutive trading days [1] - Among the stocks, 31 saw their financing balances increase by over 10%, with the largest increase recorded by Senhe Shares at 50.13% [1][2] Financing Balance Growth - The total financing balance for ChiNext stocks is 546.55 billion yuan, with a week-on-week increase of 3.797 billion yuan [1] - A total of 488 stocks experienced growth in financing balances, with 31 stocks increasing by more than 10% [1] - Senhe Shares had the highest increase in financing balance at 76.81 million yuan, with a 50.13% rise, and its stock price increased by 12.93% [1][3] - Other notable stocks with significant financing balance increases include Hongyuan Pharmaceutical and Shennong Seed Industry, with increases of 47.95% and 43.80%, respectively [1][3] Market Performance of Stocks - Among stocks with financing balance increases over 10%, the average price increase on the same day was 5.72%, with 26 stocks rising and two stocks hitting the daily limit [2] - Stocks with the highest price increases included Hongyuan Pharmaceutical (15.12%), Senhe Shares (12.93%), and Tongfei Shares (12.59%) [2] - Conversely, stocks with the largest declines included Songsheng Shares (-5.84%), Beijete (-3.35%), and Weima Agricultural Machinery (-1.56%) [2] Financing Balance Decline - A total of 459 stocks saw a decline in financing balances, with 10 stocks experiencing a decrease of over 10% [4] - The stock with the largest decline in financing balance was Xice Testing, which decreased by 37.14% to 24.07 million yuan [4][5] - Other stocks with significant declines include Jiebang Technology (-20.86%) and Kaichuang Electric (-15.72%) [4][5]